CMPS — COMPASS Pathways plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1816590 ·
Last close
$13.06
Market Cap
$1.81B
52W High
$15.87
52W Low
$4.88
ADV30
2,625,480
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -49,789,000 -253,794,000 504,561,000 433,295,000 420,028,000
Mar 2026 0 — -40,427,000 91,202,000 531,739,000 466,010,000 205,052,000
Dec 2025 0 — -58,864,000 -93,878,000 210,349,000 149,608,000 263,197,000
Sep 2025 0 — -36,612,000 -137,717,000 255,607,000 185,937,000 218,016,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-161,136,000
Investing CF
$0
Financing CF
$370,200,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-985,186,000
Inventory
—
Receivables
$15,155,000
ST Investments
—
EBIT TTM
$-391,641,000
Pretax Income TTM
$-396,831,000
Interest Exp TTM
$5,190,000
Analysts
16

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -175,290,000 -287,862,000 210,349,000 263,197,000 -52,848,000 -157,240,000
Dec 2024 0 -157,108,000 -155,122,000 213,666,000 58,971,000 154,695,000 -119,186,000
Dec 2023 0 -124,044,000 -118,464,000 275,987,000 50,243,000 225,744,000 -97,376,000
Dec 2022 0 -95,979,000 -91,505,000 197,294,000 16,014,000 181,280,000 -105,451,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$4,363,000
NetIncome TTM
$-72,215,000
OpCashFlow TTM
$0
Assets (Latest)
$210,349,000
Forward EPS
$-1.43

Max Pain — expiry 2026-10-16

max pain strike: $15.00 · spot: $13.17 · call oi: 8,581 · put oi: 2,570
Expected Move to 2026-10-16: ±$1.62 (12.34%) — implied range $11.54 – $14.79 · ATM straddle on $13.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
XNCR Xencor Inc $1.77B $23.80 —
SEPN Septerna, Inc. $1.76B $37.77 —
ZBIO Zenas BioPharma, Inc. $1.76B $26.95 —
ZYME Zymeworks Inc. $1.88B $26.52 —
SDGR Schrodinger, Inc. $1.89B $28.85 —

News headlines (Yahoo Finance, 1h cache)

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
2026-09-25 00:02 · Yahoo
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
2026-09-22 21:02 · Yahoo
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
2026-09-22 19:02 · Yahoo
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
2026-09-22 06:02 · Yahoo
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
2026-09-16 10:30 · Yahoo
COMPASS Pathways (CMPS) Stock May Be Fully Priced On Phase 3 Data
2026-09-16 06:11 · Yahoo
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
2026-09-15 10:30 · Yahoo
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
2026-09-10 12:00 · Yahoo
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
2026-09-10 10:35 · Yahoo
Compass Pathways to Participate in Investor Conferences the Week of September 14th
2026-09-10 10:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.